Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study

Fig. 3

Comparison of treatment regimens ad therapeutic outcomes of IgG4-RD patients in hypocomplementemia group and normal complement group. a Comparison of initial GCs dose between hypocomplementemia group (group 1) and normal complement group (group 2). b The first-line therapies for hypocomplementemia group (group 1) and normal complement group (group 2). c The changes in IgG4-RD RI scores during the 48 months of follow-up in hypocomplementemia group (n = 38) and normal group (n = 105). **P < 0.01, ***P < 0.001. d Kaplan-Meier survival analysis suggested no significant difference of relapse-free survival between two groups(P = 0.401). e Relapse rates of four subgroups were compared. Low+GC hypocomplementemia group treated with GCs, Nor+GC normal complement group treated with GCs, Low+Com hypocomplementemia group treated with combined therapy (GCs plus IM), Nor+Com normal complement group treated with treated with combined therapy (GCs plus IM). Chi-Square test showed no statistical difference in four subgroups

Back to article page